Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
October 25th 2023Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Read More
Nivolumab Plus Chemotherapy Treatment Followed By Surgery Improved EFS in Patients With NSCLC
October 25th 2023Compared to placebo plus chemotherapy, nivolumab plus chemotherapy had also improved event-free survival and both pathological complete response and major pathologic response rates.
Read More
Nasopharyngeal Swabs Most Sensitive for Pneumococcal Detection in Infants
October 20th 2023Study authors suggest that saliva samples can be a complementary testing method to provide additional information on pneumococcal carriage and serotypes that may be undetected by nasopharyngeal testing.
Read More
Expert: Celebrating Pharmacists’ Role in Health Care, Changes in the Profession
October 19th 2023The assistant program director at Mayo Clinic discusses the significance of pharmacists’ role in health care, changes throughout the industry, and her passion for mentoring pharmaceutical students.
Read More
Study Results Indicate Precision Therapies Make Up Approximately Half of FDA-Approved Oncology Drugs
October 19th 2023This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.
Read More
Rebyota Found Safe, Effective in Preventing Recurring Clostridioides Difficile Infection
October 16th 2023Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.
Read More
Follow-Up Survey Indicates Cancer Centers Continue to Experience Chemotherapy Shortages
October 12th 2023Larger institutions have continued to treat patients who needed carboplatin or cisplatin; however, the survey results don’t include smaller cancer centers that may face access challenges.
Read More